Liver Cancer Incidence is on the Rise in the United States (05/25/2010)
From 2001 to 2006, the incidence of hepatocellular carcinoma (HCC) increased significantly with an average increase of 3.5% annually. This analysis was recently reported in the Centers for Disease Control and Prevention’s (CDC) Morbidity and Mortality Weekly Report.

Combination Chemotherapy Improves Survival with Biliary Tract Cancer (05/17/2010)
According to the results of a Phase III clinical trial, treatment of locally advanced or metastatic biliary tract cancer with a combination of Gemzar® (gemcitabine) and cisplatin results in better survival and a lower risk of cancer progression than treatment with Gemzar alone.

Liver Cancer Often Linked to Diabetes (05/04/2010)
Diabetes increases the risk of hepatocellular carcinoma (HCC) and may account for a greater number of HCC cases in the United States than any other single HCC risk factor. These results were presented at the 101^st annual meeting of the American Association for Cancer Research.

Sutent® Not Effective for Advanced Liver Cancer (07/10/2009)
In a Phase II clinical trial, patients with inoperable, advanced hepatocellular (liver) cancer did not benefit from treatment with the targeted therapy Sutent® (sunitinib). The results of this study were published in Lancet Oncology.

Women with Hypothyroidism at Increased Risk of Liver Cancer (06/22/2009)
Long-term hypothyroidism in women significantly increases the risk of developing hepatocellular carcinoma (liver cancer), according to the results of a study published in Hepatology.

Combination of Chemotherapy Drugs Improves Survival with Biliary Tract Cancer (05/20/2009)
According to the results of a Phase III clinical trial that will be presented at the 2009 annual meeting of the American Society of Clinical Oncology (ASCO), treatment of gallbladder or bile duct cancer with a combination of Gemzar® (gemcitabine) and cisplatin results in better survival and a lower risk of cancer progression than treatment with Gemzar alone.

Hepatocellular Carcinoma

Recurrent

Screening/Prevention

Liver Cancer Incidence is on the Rise in the United States (05/25/2010)
From 2001 to 2006, the incidence of hepatocellular carcinoma (HCC) increased significantly with an average increase of 3.5% annually. This analysis was recently reported in the Centers for Disease Control and Prevention’s (CDC) Morbidity and Mortality Weekly Report.

Stage IV

Stages I-III